E-LIB Suche - Ergebnisse für: Buter, Anne

1

Efficacy and Safety of Panitumumab in Patients With RAF/RAS..:

Spiekman, Ilse A C ; Geurts, Birgit S ; Zeverijn, Laurien J...
The Oncologist. 29 (2023) 5 - p. 431-440 , 2023

Link: https://doi.org/10.1093/..

2

Chiral Amplification of Phosphoramidates of Amines and Amin..:

Dašková, Vanda ; Buter, Jeffrey ; Schoonen, Anne K....
Angewandte Chemie. 133 (2021) 20 - p. 11220-11226 , 2021

Link: https://doi.org/10.1002/..

3

Chiral Amplification of Phosphoramidates of Amines and Amin..:

Dašková, Vanda ; Buter, Jeffrey ; Schoonen, Anne K....
Angewandte Chemie International Edition. 60 (2021) 20 - p. 11120-11126 , 2021

Link: https://doi.org/10.1002/..

4

Subtherapeutic Exposure of Ganciclovir in Children Despite ..:

Marfil, Sjanene ; Märtson, Anne-Grete ; Toren-Wielema, Marlous...
Therapeutic Drug Monitoring. 45 (2022) 2 - p. 269-272 , 2022

Link: https://doi.org/10.1097/..

5

Chiral Amplification of Phosphoramidates of Amines and Amin..:

Dašková, Vanda ; Buter, Jeffrey ; Schoonen, Anne K...
https://research.rug.nl/en/publications/8a88a060-3962-4927-9e4a-75090e46fe2e. , 2021

Link: https://hdl.handle.net/1..

6

Chiral Amplification of Phosphoramidates of Amines and Amin..:

Dašková, Vanda ; Buter, Jeffrey ; Schoonen, Anne K...
https://dspace.library.uu.nl/handle/1874/412062. , 2021

Link: https://dspace.library.u..

7

Chiral Amplification of Phosphoramidates of Amines and Amin..:

Dašková, Vanda ; Buter, Jeffrey ; Schoonen, Anne K...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252365/. , 2021

Link: http://www.ncbi.nlm.nih...

8

Subtherapeutic Exposure of Ganciclovir in Children Despite ..:

Marfil, Sjanene ; Märtson, Anne-Grete ; Toren-Wielema, Marlous...
https://research.rug.nl/en/publications/2f353fe4-924e-481f-b94b-1ee9ce4eeecc. , 2023

Link: https://hdl.handle.net/1..

9

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..

10

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..

11

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..

12

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..

13

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..

14

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..

15

Prevalence and clinical outcomes of poor immune response de..:

Jourdain, Gonzague ; Soriano-Arandes, Antoni ; Collins, Intira...
info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz253. , 2019

Link: https://hal.science/hal-..